Regulatory

FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment

Pharmaceutical Business Review

This approval covers patients with ccRCC who are at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.

Oncology

Read full story

pharminent June 15, 2026 (Last updated: June 15, 2026)

Pharmaceutical Business Review

This approval covers patients with ccRCC who are at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions.

Oncology

Read full story

Related Stories

Novo Nordisk comeback stirs as Wegovy pill wins UK approval

Lilly wins new FDA approval for eczema drug Ebglyss

Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug

You May Have Missed

Eisai claims UK grant to expand manufacturing site

Key pipeline drug for Lundbeck delivers in Cushing syndrome

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Lilly sees quick return on $2.3B Ajax buy as blood cancer drug shows early efficacy